Joincare Pharmaceutical Group Industry Co., Ltd. (stock code: 600380.SH) is a leading Chinese pharmaceutical enterprise headquartered in Shenzhen, Guangdong Province. The company was originally incorporated in December 1992 as Shenzhen Tai Tai Pharmaceutical Co., Ltd. and was listed on the Shanghai Stock Exchange in 2001. It underwent a name change to Joincare in 2003 to reflect its broader strategic ambitions beyond the original 'Tai Tai' oral liquid brand. Today, Joincare operates as a diversified healthcare group with business segments spanning chemical formulations, active pharmaceutical ingredients (APIs) and intermediates, traditional Chinese medicine (TCM), biologics, diagnostic reagents and equipment, and health supplements.

The company's controlling subsidiary, Livzon Pharmaceutical Group Inc. (丽珠集团, 000513.SZ), represents a significant portion of consolidated revenue and profit, contributing approximately 60% of group revenue and the majority of net income. This parent-subsidiary structure creates both synergies and complexities: Livzon provides a deep pipeline in biologics and specialty pharmaceuticals, while Joincare's standalone operations focus on respiratory inhalation drugs, APIs, and consumer healthcare products. The dual-platform structure has been a source of strategic flexibility but also introduces consolidation dynamics that can obscure underlying business trends.

For FY2025, Joincare reported consolidated revenue of RMB 15,216 million, down 2.58% year-over-year, and net income attributable to shareholders of RMB 1,336 million, down 3.68%. This marked the third consecutive year of revenue and profit decline, reflecting the persistent impact of China's volume-based procurement (VBP) policy on the company's mature product portfolio. Basic earnings per share stood at RMB 0.73, and the company proposed a dividend of RMB 2.20 per 10 shares (tax inclusive), maintaining a consistent shareholder return policy.

Joincare's business model is built on a multi-segment platform that combines high-margin branded formulations, cost-competitive API manufacturing, and consumer healthcare products. This diversification provides natural hedging against sector-specific headwinds, though it also means that the company's overall growth trajectory is often a blended outcome of disparate business dynamics.

Chemical Formulations (化学制剂) represent the largest revenue pillar, generating RMB 7,287 million in FY2025, or 47.9% of total revenue, albeit with a 5.64% year-over-year decline. Within this segment, respiratory inhalation drugs are the strategic focus. Joincare is recognized as a pioneer in domestic inhalation drug development, with products including budesonide inhalation suspension, tobramycin inhalation solution, and first-to-market generic versions of fluticasone propionate and salmeterol/fluticasone combinations. The company's respiratory portfolio has successfully broken the long-standing monopoly of multinational corporations such as AstraZeneca and GSK in the Chinese inhalation market. Notably, innovative drug revenue as a proportion of respiratory formulation sales exceeded 25% in FY2025, up from a negligible base just a few years ago.

APIs and Intermediates (原料药及中间体) constitute the second-largest segment at RMB 4,709 million (30.9% of revenue), declining 5.76% year-over-year. Key products include 7-ACA (7-aminocephalosporanic acid), meropenem, and imipenem intermediates. While this segment operates at lower margins (gross margin of 34.43% versus 77.99% for formulations), it provides vertical integration benefits and export revenue. The company is strategically shifting toward higher-value-added APIs to improve profitability.

TCM Formulations (中药制剂) contributed RMB 1,686 million (11.1% of revenue), growing 14.47% year-over-year. Key products include Livzon's Shenqi Fuzheng Injection and other proprietary Chinese medicines. Health Supplements (保健食品) generated RMB 516 million (3.4% of revenue), surging 36.96% with an impressive gross margin of 79.0%. The flagship 'Yingpai' (鹰牌) American ginseng series achieved its best half-year sales in nearly a decade, driven by brand investment and omnichannel distribution. Biologics (生物制品) contributed RMB 201 million (1.3% of revenue), growing 17.5%, and Diagnostic Reagents and Equipment (诊断试剂及设备) generated RMB 657 million (4.3% of revenue), declining 8.56%.

In the Chinese inhalation drug market, Joincare ranks as the sixth-largest group by sales in public medical institutions, according to Menet data, with a market share that has been steadily climbing. The market is dominated by AstraZeneca and GSK at the top, followed by domestic leaders including Hengrui Pharmaceuticals, Chia Tai Tianqing, and Betta Pharmaceuticals. Joincare distinguishes itself through its early-mover advantage in complex inhalation formulations, having established Shanghai Fangyu in 2013 as a dedicated inhalation R&D platform.

The competitive landscape in inhalation drugs is intensifying. According to Menet, the Chinese inhalation drug market exceeded RMB 20 billion in sales at public medical institutions in 2025, with respiratory system drugs accounting for over 80% of the total. The market is undergoing significant reshuffling, with domestic players gaining ground. Joincare's key competitive strengths include a broad portfolio of 10 marketed inhalation products, robust hospital channel coverage, and established clinical relationships in respiratory medicine. However, the segment faces mounting pressure from VBP, with multiple inhalation products having been included in national procurement rounds, compressing prices and margins.

In the API segment, Joincare competes primarily on cost and quality. The 7-ACA market is relatively consolidated, with Joincare among the top producers. Meropenem prices, which experienced a sharp correction in recent years, have shown signs of stabilization and recovery. In health supplements, Joincare competes with established brands such as By-Health and H&H International, leveraging its 'Yingpai' brand heritage and expanding distribution into lower-tier markets and online channels. The supplement segment's 79% gross margin makes it an attractive profit contributor despite its relatively small revenue base.

While Joincare operates in the pharmaceutical sector rather than semiconductors, the company has made significant progress in integrating artificial intelligence into its drug discovery and manufacturing processes. This AI alignment represents a key differentiator in the Chinese pharmaceutical industry, where digital transformation has become a strategic priority under the national 'Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030).'

In R&D, Joincare has deployed localized versions of mainstream AI models, including DeepSeek, to accelerate target identification, molecular design, and clinical trial optimization. The company's collaboration with Tencent Quantum Laboratory on a biosynthetic gene cluster prediction algorithm has resulted in published research and a joint national invention patent application, providing technical support for API development and synthetic biology. In the COPD research area, AI-assisted approaches have shortened the lead compound discovery cycle to approximately six months, a significant acceleration compared to traditional methods. The Mapacixavir dry suspension project leveraged AI-assisted clinical strategy formulation to achieve a 'Phase I skip to Phase III' regulatory breakthrough.

In manufacturing, Joincare applies AI to optimize production processes and predict capacity requirements. Historical process data modeling has increased the yield of imipenem intermediates by over 5 percentage points while reducing unit consumption. In commercialization, AI agents have been deployed to provide services to nearly 100,000 chronic disease patients, using predictive models to identify health risks and improve patient engagement. This AI-enabled patient service platform is particularly valuable in the respiratory and chronic disease management space, where long-term patient adherence is critical to therapeutic outcomes and brand loyalty.

The company has expressed ongoing interest in exploring AI-driven drug discovery partnerships and is actively evaluating collaboration opportunities in this domain. While AI does not fundamentally change Joincare's core business model, it enhances R&D efficiency, manufacturing productivity, and patient engagement—all of which are key competitive levers in the increasingly innovation-driven Chinese pharmaceutical market.

Joincare's customer base is primarily institutional, comprising hospitals, pharmacies, and healthcare distributors across China, with a growing international footprint. The company's domestic revenue is heavily concentrated in public medical institutions, where its respiratory and TCM products have established clinical adoption. However, the VBP policy has fundamentally altered the hospital procurement landscape, shifting volume toward lower-priced generics and placing greater emphasis on formulary access and cost-effectiveness.

Geographically, China remains the dominant market, accounting for approximately 82% of total revenue. In FY2025, overseas revenue reached RMB 2,768 million, up 4.78% year-over-year, representing about 18.2% of total revenue. The international business is primarily API exports to regulated markets including the European Union, where the company sells directly to customers. While EU sales remain modest as a proportion of total exports, the company has been expanding its regulatory footprint. Joincare's subsidiary Livzon has obtained PIC/S GMP certification from Malaysia's National Pharmaceutical Regulatory Agency, signaling quality management systems that meet international standards.

In terms of international expansion, the company completed the acquisition of Vietnam's IMP (Imexpharm) in May 2025, which was consolidated into financial statements from that point. IMP operates EU-GMP certified manufacturing facilities, providing Joincare with a local production base in Southeast Asia and a platform for regional market expansion. Additionally, the company's first overseas API factory is under construction in Jakarta, Indonesia, focused on producing specialty APIs that meet international standards. In FY2025, Joincare and Livzon products obtained marketing approvals in multiple countries including Pakistan, Uzbekistan, Indonesia, Brazil, and Malaysia. The company's formulation export strategy is gradually evolving from simple product registration to a more systematic approach involving regional depth and localized production.

Joincare's economic moat derives from several interrelated sources: regulatory barriers in complex inhalation formulations, brand equity in consumer healthcare, vertical integration in APIs, and an emerging innovation pipeline that is beginning to differentiate the company from pure-play generic manufacturers.

The most significant moat source is the company's early-mover advantage in inhalation drug technology. Complex inhalation formulations—particularly dry powder inhalers and pressurized metered-dose inhalers—require sophisticated device engineering, particle engineering, and bioequivalence capabilities that create high barriers to entry. Joincare's decade-plus investment in this area, starting with the establishment of Shanghai Fangyu in 2013, has resulted in a portfolio of 10 marketed inhalation products and a deep pipeline of next-generation candidates. The company's ability to develop generic equivalents of GSK's Advair (salmeterol/fluticasone) and other complex inhalation devices demonstrates technical capabilities that few Chinese companies possess.

Brand equity represents a second moat source. The 'Yingpai' brand in health supplements and the 'Tai Tai' brand heritage provide consumer recognition and trust that are difficult to replicate. The health supplement segment's ability to grow 37% year-over-year despite a high base and intense competition speaks to the strength of this consumer franchise. Branded consumer healthcare products typically command higher margins and exhibit greater pricing power than prescription pharmaceuticals, providing a ballast against VBP-driven margin compression.

Vertical integration in APIs provides a cost advantage and supply chain security. Joincare's API operations supply internal formulation production while also generating external revenue. This integration is particularly valuable in the current environment of supply chain disruption and raw material price volatility. The planned Indonesian API factory will further enhance cost competitiveness by locating production closer to Southeast Asian markets and potentially benefiting from lower operating costs.

The emerging innovation pipeline represents the most important future moat source. With over 10 Class 1 innovative drug candidates in the respiratory space alone, including the recently approved Mapacixavir and the Phase III-stage IL-17A/F antibody, Joincare is building a portfolio of proprietary products that are less susceptible to VBP price erosion. The TSLP antibody for COPD, the FIC-potential PREP inhibitor, and the Nav1.8 inhibitor for postoperative pain all target large markets with significant unmet need. If successfully commercialized, these products could transform Joincare from a generic-driven company to an innovation-driven one, fundamentally altering its competitive positioning and margin profile.

Joincare's most distinctive competitive advantage is its dual-engine strategy combining high-barrier complex generic formulations with an increasingly robust innovative drug pipeline. This approach allows the company to generate near-term cash flow from complex generics while investing in long-term innovation, a balanced model that many Chinese pharmaceutical companies struggle to execute.

In the respiratory space specifically, Joincare has built an unmatched combination of breadth and depth. The company's 10 marketed inhalation products cover the full spectrum of delivery technologies—nebulizers, dry powder inhalers, and metered-dose inhalers—and address major respiratory conditions including asthma and COPD. This portfolio breadth enables Joincare to offer comprehensive respiratory solutions to hospitals and physicians, strengthening its bargaining position and customer loyalty. The company's dedicated respiratory sales force, with deep clinical relationships in respiratory medicine, is a valuable intangible asset that supports both generic and innovative product launches.

Another unique advantage is the company's ability to leverage AI across the entire drug development value chain, from target identification through commercial patient services. While many Chinese pharmaceutical companies have announced AI initiatives, Joincare's deployment appears to be among the more advanced in terms of actual implementation and measurable outcomes. The reduction of COPD lead compound discovery time to approximately six months and the 5-percentage-point yield improvement in imipenem production demonstrate tangible benefits that directly impact R&D costs and manufacturing margins.

The health supplement franchise, though relatively small in revenue terms, represents a high-margin, consumer-facing business that provides diversification and brand equity benefits. The 'Yingpai' brand's near-decade-best performance in the first half of 2025, with gross margins exceeding 79%, illustrates the profit potential of this segment. As the company continues to expand distribution channels and product offerings in this space, the supplement division could become a more significant contributor to group profitability.

Joincare's R&D expenditure in FY2025 reached RMB 1,429 million, representing 9.39% of revenue—a level that places the company among the more R&D-intensive players in the Chinese pharmaceutical sector. Of this total, R&D expenses (as distinct from capitalized development costs) amounted to RMB 1,273 million, a decrease of 11.31% year-over-year, reflecting the company's focus on late-stage programs with higher probability of success. The capitalization rate was 14.17%, indicating a conservative approach to financial reporting.

The company's R&D organization is structured around several platforms: the Shanghai Fangyu inhalation technology platform, the Livzon Biologics antibody discovery and development platform, and various chemical synthesis and process chemistry groups focused on APIs and intermediates. This multi-platform structure enables parallel development across different therapeutic modalities and technology domains.

The innovation pipeline has reached an inflection point. The approval of Mapacixavir capsule (壹立康) in December 2025 marked the company's first Class 1 innovative drug approval and the beginning of a new phase of commercialized innovation. Mapacixavir is a dual-action antiviral for both influenza A and B with a differentiated single-dose oral regimen, targeting a market with high consumer awareness and significant seasonal demand. The pediatric formulation (dry suspension) has advanced to Phase III clinical trials and is expected to complete enrollment and submit for approval.

In the immunology space, the IL-17A/F monoclonal antibody LZM012 achieved its primary endpoint in Phase III trials for psoriasis, demonstrating non-inferiority and superiority compared to secukinumab (Cosentyx), with a PASI100 response rate of 49.5% versus 40.2% for the comparator. This product has been submitted for marketing approval with priority review status. The ankylosing spondylitis indication has also completed Phase III trials. In respiratory innovation, the TSLP antibody for COPD has entered Phase III, with asthma Phase II trials running in parallel. The PREP inhibitor, a potential first-in-class oral treatment for COPD, is in Phase II. The Nav1.8 inhibitor for postoperative pain has completed Phase II and is expected to enter Phase III by year-end. Early-stage programs include a novel beta-lactamase inhibitor and an FXI bispecific antibody, both in Phase I.

The company's technology capabilities extend beyond traditional small molecules and antibodies to include synthetic biology and gene cluster prediction, developed in collaboration with Tencent Quantum Laboratory. This capability supports the development of fermentation-based APIs and novel biosynthetic routes, potentially reducing production costs and enabling the manufacture of complex natural product derivatives.

The Chinese pharmaceutical industry is undergoing a profound structural transformation, driven by the twin forces of healthcare cost containment through VBP and policy support for innovation. In 2025, the 11th round of national VBP introduced significant rule optimizations, including 'stable clinical' provisions that allow brand-specific reporting, 'anti-involution' mechanisms to prevent destructive price competition, and 'anchor price' systems to establish reasonable pricing floors. While these reforms are intended to shift procurement from pure price competition to value-based competition, the cumulative effect of multiple VBP rounds continues to exert downward pressure on generic drug prices.

The innovation landscape has never been more supportive. In 2025, the NMPA approved 51 new drugs, of which 71% were domestic innovations, and the proportion of first-in-class (FIC) pipeline candidates reached 22%. The National Healthcare Security Administration and National Health Commission jointly issued measures to support high-quality innovation, establishing a full-chain support system covering R&D, market access, and payment. Critically, newly negotiated innovative drugs entering the medical insurance catalog are exempt from VBP during their agreement period, protecting the profit margins and R&D investment incentives of innovative drug developers. The first commercial health insurance innovative drug catalog, published in December 2025, creates an additional payment channel for high-value therapies.

The inhalation drug market in China, Joincare's core strategic focus, exceeded RMB 20 billion in sales at public medical institutions in 2025, with respiratory system drugs accounting for over 80%. The market remains dominated by multinational corporations AstraZeneca and GSK, but domestic players including Joincare, Hengrui, and Betta are steadily gaining share. The competitive dynamic is shifting from generic substitution of off-patent MNC products toward genuine innovation in inhalation technology—novel devices, new chemical entities, and biologics delivered via inhalation. Joincare's JKN2404 inhalation suspension, a Class 1 innovative drug that received clinical approval in 2025, exemplifies this shift toward indigenous innovation.

The API industry faces a mixed outlook. While demand for high-quality APIs remains robust globally, price competition from Indian and Chinese manufacturers has compressed margins in commodity APIs. Companies with cost advantages, regulatory certifications (EU-GMP, PIC/S GMP), and proprietary processes are better positioned to maintain profitability. Joincare's strategy of shifting toward higher-value specialty APIs, combined with its planned Indonesian manufacturing base, aligns with this industry trend.

Joincare Pharmaceutical Group is a company in transition, navigating the difficult passage from a generic and API-dependent business model to an innovation-driven one. The FY2025 results reflect the challenges of this transition: three consecutive years of revenue and profit decline, persistent VBP pressure on mature products, and the lag between R&D investment and commercial returns.

Yet there are compelling reasons for optimism about the company's medium-term prospects. The approval of Mapacixavir as the first Class 1 innovative drug represents a genuine milestone, not merely a regulatory formality. The product addresses a large, well-defined market (influenza treatment) with a differentiated profile (single-dose oral regimen for both influenza A and B), and the company's commercial infrastructure in respiratory medicine provides a ready channel for launch. The IL-17A/F antibody, if approved, would compete in the large psoriasis and spondyloarthritis markets, where the company's Livzon subsidiary has established biologics manufacturing and commercialization capabilities.

The health supplement business provides a high-margin, consumer-driven growth engine that is largely insulated from healthcare policy risk. With 37% revenue growth and 79% gross margins, this segment deserves greater strategic emphasis and could become a more significant value driver over time.

The company's financial position is sound. Operating cash flow of RMB 3.89 billion comfortably covers dividend payments and R&D investment. Net cash position (cash minus total debt) is strongly positive, with total cash of RMB 14.68 billion against total debt of RMB 3.91 billion as of the most recent quarter. The debt-to-equity ratio of 15.92% is conservative, providing ample capacity for strategic investments or acquisitions. The company's dividend policy—RMB 2.20 per 10 shares in FY2025—represents a payout ratio of approximately 30%, balancing shareholder returns with reinvestment needs.

However, investors should be cognizant of the key risks. VBP pressure on mature inhalation products and APIs may persist longer than expected, delaying the inflection in group revenue. The commercialization of innovative drugs carries inherent execution risk, and the competitive landscape in psoriasis, COPD, and influenza is intensifying. The company's reliance on Livzon for the majority of consolidated profit means that Livzon-specific challenges (such as the recent decline in chemical formulation and TCM revenue at the subsidiary level) can disproportionately impact group financials.

On balance, Joincare presents an investment case of a deeply undervalued, cash-generative pharmaceutical company at an inflection point in its innovation cycle. The current valuation—approximately 13-14x trailing earnings and 1.1x book value—appears to price in continued earnings pressure but offers limited downside given the company's strong balance sheet and dividend support. The successful execution of the innovative drug pipeline and a stabilization of the core generic business could catalyze a re-rating as the market begins to recognize Joincare not as a declining generic manufacturer but as an emerging respiratory and immunology innovator.

The enterprise quality, viewed holistically, is above average for the Chinese pharmaceutical sector. The company possesses durable competitive advantages in inhalation technology, a credible innovation pipeline, a high-margin consumer franchise, a conservative balance sheet, and a consistent capital return policy. These attributes, combined with the current valuation discount, make Joincare a name worth monitoring closely as its transformation unfolds.